<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA"/>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 22,184 shares of the company's stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.50, for a total value of $11,092.00. Following the completion of the transaction, the director owned 1,104,312 shares of the company's stock, valued at approximately $552,156. This represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p><p>Luke Evnin also recently made the following trade(s): </p><ul><li>On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total value of $36,934.85. </li><li>On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $28,336.50. </li><li>On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40. </li><li>On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16. </li><li>On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70. </li><li>On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18. </li><li>On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10. </li><li>On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40. </li><li>On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36. </li><li>On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62. </li></ul><h2>Werewolf Therapeutics Trading Up 2.2%</h2><hr/><hr/><p>Werewolf Therapeutics stock opened at $0.44 on Thursday. The stock has a market cap of $21.29 million, a P/E ratio of -0.35 and a beta of 0.41. The stock has a 50 day moving average of $0.79 and a 200-day moving average of $0.79. Werewolf Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $2.38. </p><p>Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04.  As a group, equities analysts predict that  Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Werewolf Therapeutics</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new stake in  Werewolf Therapeutics in the second quarter worth $409,000.  Renaissance Technologies LLC increased its position in  Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock worth $429,000 after buying an additional 221,766 shares during the period.  Citadel Advisors LLC acquired a new stake in  Werewolf Therapeutics in the third quarter worth $304,000.  Vanguard Group Inc. increased its position in  Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock worth $2,774,000 after buying an additional 109,796 shares during the period.  Finally, Marshall Wace LLP acquired a new stake in  Werewolf Therapeutics in the second quarter worth $113,000. 64.84% of the stock is owned by institutional investors and hedge funds. </p><h2>Analysts Set New Price Targets</h2><p>Several research firms recently issued reports on HOWL. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics presently has an average rating of &#34;Hold&#34; and an average price target of $3.75.</p><p><b>View Our Latest Report on HOWL</b></p><h2>Werewolf Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.  </p><p>Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Werewolf Therapeutics</li><li>Freight Boom: The Hormuz Blockade Payday</li><li>The Palantir Paradox—Record Numbers and a Stock That Won't Cooperate</li><li>TJX Companies Fires on All Cylinders With 9% Revenue Growth</li><li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9XTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9XTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Werewolf Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Werewolf Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>SpaceX eyes a 1.75 trillion valuation - here's what to know</p><p>Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260204150656_pushelon-6083103640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260204150656_pushelon-6083103640.jpg"/></p><div><p>$30 stock to buy before Starlink goes public (WATCH NOW!)</p><p>In the next 3 minutes…  James Altucher – legendary investor and venture capitalist…  And someone who’s kno...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODEzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODEzNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="250" original-src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png"/></p><div><p>My feud with Zohran Mamdani</p><p>Emmy-winning analyst releases his next big story  Whitney Tilson shocked the nation on 60 Minutes when he ac...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="450" height="156" original-src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png"/></p><div><p>Iran War Shock: What I Was Told In That Private Meeting</p><p>You’re Being LIED To About The Iran War  Forget EVERYTHING you’ve heard about the Iran war.  Especially th...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg"/></p><div><p>Why this tiny stock may move before the SpaceX IPO drops</p><p>The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk2Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk2Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260512161034_pushlaptop-1839876640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260512161034_pushlaptop-1839876640.jpg"/></p><div><p>Your book attached</p><p>Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ0OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ0OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260430135545_pushelonnew-2.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260430135545_pushelonnew-2.jpg"/></p><div><p>SpaceX IPO hides a much bigger story</p><p>The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself.  ...</p><p><span>Weiss Ratings</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIyMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/04/Picture6.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="250" original-src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/04/Picture6.png"/></p><div><p>Satellite Images Spot Potential $10 Trillion Discovery</p><p>'Dark Energy': Elon Musk's Next Potential $10 Trillion Move  A highly secure site in West Texas now houses a...</p><p><span>Altimetry</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTEwOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTEwOA"/></p></div></div></div>                     </div>                 </div></div>

HOWL

IBBQ

LABU

<p>Luke Evnin, Director of Werewolf Therapeutics (NASDAQ:HOWL), sold 22,184 shares at $0.50 each, totaling $11,092, reducing his stake by 1.97%. Following this, he owns 1,104,312 shares valued at approximately $552,156. This transaction was part of a pre-arranged trading plan. Evnin has made several other sales recently, with varying amounts and prices. The stock is currently trading at $0.44, with a market cap of $21.29 million.</p>

Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock